The safety profile of tadalafil as prescribed in general practice in England: Results from a prescription-event monitoring study involving 16 129 patients

BJU International

Volumn 103, Issue 4, 2009, Pages 506-514

  Hazell, Lorna ^a   Cornelius, Victoria ^b   Wilton, Lynda V ^b   Shakir, Saad A W ^b  

^a DRUG SAFETY RESEARCH UNIT   (United Kingdom)

^b NONE

Author keywords

Ischaemic heart disease; Mortality; Myocardial infarction; Postmarketing surveillance; Prescription event monitoring; Tadalafil

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; NITRATE; TADALAFIL;

ADULT; AGED; ARTICLE; BACKACHE; BRADYCARDIA; CAUSE OF DEATH; CONFUSION; CONJUNCTIVITIS; DEMOGRAPHY; DIABETES MELLITUS; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EJACULATION DISORDER; FAINTNESS; FALLING; FLUSHING; GENERAL PRACTICE; HEADACHE; HEART PALPITATION; HEMOSPERMIA; HICCUP; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OPTIC NERVE DISEASE; PENILE BENDING; PENILE CURVATURE; PENIS DISEASE; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; RASH; RISK FACTOR; SIDE EFFECT; TACHYCARDIA; THORAX PAIN; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT; URTICARIA; VISUAL DISORDER;

ADULT; AGED; AGED, 80 AND OVER; CARBOLINES; COHORT STUDIES; ENGLAND; ERECTILE DYSFUNCTION; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PHOSPHODIESTERASE INHIBITORS; PRODUCT SURVEILLANCE, POSTMARKETING; QUESTIONNAIRES; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 59249107352     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.08000.x     Document Type: Article

References (30)

1. Cialis. Summary of Product Characteristics. Lilly Basingstoke, 2002
2. Reffelman T, Kloner R. Pharmacotherapy of erectile dysfunction: focus on cardiovascular safety. Expert Opin Drug Saf 2005 4 : 531 40
3. Reffelman T, Kloner RA. Cardiovascular effects if phosphodiesterase 5 inhibitors. Curr Pharm Des 2006 12 : 3485 94
4. Kirby M, Jackson G, Simonsen U. Endothelial dysfunction links erectile dysfunction to heart disease. Int J Clin Pract 2005 59 : 225 9
5. Mittleman M, Glasser DB, Orazem J. Clinical trials of sildenafil citrate (Viagra) demonstrate no increase risk of myocardial infarction and cardiovascular death compared with placebo. Int J Clin Pract 2003 57 : 597 600
6. Shakir S-AW, Wilton LV, Boshier A, Layton D, Heeley E. Cardiovascular events in users of sildenafil: results from the first phase of prescription-event monitoring in England. BMJ 2001 322 : 651 2
7. Hazell L, Boshier A, Harris S, Wilton LV, Shakir SAW. An observational cohort study investigating the cardiovascular safety of tadalafil when prescribed in primary care in England; focusing on mortality due to ischaemic heart disease. BJU Int 2007 99 : 387 93
8. Kloner RA, Jackson G, Hutter AM et al. Cardiovascular safety update of Tadalafil: retrospective analysis of data from placebo-controlled and open-label clinical trials of Tadalafil with as needed, three times-per-week or once-a-day dosing. Am J Cardiol 2006 97 : 1778 84
9. Fraunfelder FW. Visual side effects associated with erectile dysfunction agents. Am J Ophthalmol 2005 140 : 723 4
10. Bella AJ, Brant WO, Lue TF, Brock GB. Non-arteritic anterior ischemic optic neuropathy (NAION) and phosphodiesterase type-5 inhibitors. Can J Urol 2006 13 : 3233 8
11. Cialis. Summary of Product Characteristics. Basingstoke : Lilly, 2006
12. Shakir SAW. Prescription-event monitoring. In Mann RD, Andrews EB, Pharmacovigilance, 2nd edn. Chichester, UK : John Wiley & Sons Ltd, 2007 : 307 16
13. Office for National Statistics. Mortality Statistics-general. Review of the Registrar General on Deaths in England and Wales, 2003. Report no. 36 Report Series DH1. London : Stationery Office, 2003
14. International Statistical Classification of Diseases and Related Health Problems (1992-4), 10th Revision. Geneva : WHO, 2003
15. International Ethical Guidelines for Biomedical Research Involving Human Subjects. Geneva, Switzerland : CIOMS/WHO, 2002
16. Guidelines on the Practice of Ethics Committees in Medical Research Involving Human Subjects, 3. London : Royal College of Physicians of London, 1996
17. Confidentiality. Protecting and Providing Information - Frequently Asked Questions (Question 7). London : General Medical Council, 2004 : 9
18. Lilly ICOS LLS. Cialis (Tadalafil) Tablets. Available at: http://www.fda.gov/cder/foi/label/2003/021368lbl.pdf. Accessed November 2003
19. FDA. Alert for Healthcare Professional - Sildenafil Citrate (marketed as Viagra). Available at: http://www.fda.gov/cder/drug/InfoSheets/HCP/ sildenafilHCP.htm. Accessed July 2005
20. Hatzichristou D. Phosphodiesterase 5 inhibitors and nonarteritic anterior ischemic optic neuropathy (NAION): coincidence or causality? J Sex Med 2005 2 : 751 8
21. Hayreh SS. Erectile dysfunction drugs and non-arteritic anterior ischemic optic neuropathy: is there a cause and effect relationship? J Neuroophthalmol 2005 25 : 295 8
22. Gorkin L, Hvidsten K, Sobel RE, Siegel R. Sildenafil citrate use and the incidence of nonarteritic anterior ischemic optic neuropathy. Int J Clin Pract 2006 60 : 500 3
23. Hattenhauer MG, Leavitt JA, Hodge DO et al. Incidence of nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 1997 123 : 103 7
24. Johnson LN, Arnold AC. Incidence of nonarteritic and arteritic anterior ischemic optic neuropathy. Population-based study in the state of Missouri and Los Angeles County, California. J Neuroophthalmol 1994 14 : 38 44
25. Joint Health Surveys Unit. Health Survey for England. A Summary of Key Findings; a Survey Carried Out on Behalf of the Department of Health. Available at: http://www.dh.gov.uk/assetRoot/04/09/89/09/04098909.pdf Accessed 3 October, 2005
26. Office for National Statistics. Mortality Statistics 2003: General. Health Statistics Quarterly, no. 28 Winter, 2005. London : Stationery Office, 2005
27. Jackson G, Rosem RC, Kloner RA, Kostis JB. The second Princeton consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine. J Sex Med 2006 3 : 28 36
28. Smith GD, Frankel S, Yarnell J. Sex and death: are they related? Findings of the Caerphilly cohort study. BMJ 1997 315 : 1641 4
29. Shakir SAW. Prescription-event monitoring. In Strom BL ed. Pharmacoepidemiology, 4th edn. Chichester : John Wiley & Sons Ltd, 2005 : 203 16
30. Jackson G. PDE-5 inhibitors: looking beyond ED. Int J Clin Pract 2003 57 : 159 60